Literature DB >> 1661088

Hypoxic contraction of canine coronary arteries: role of endothelium and cGMP.

T Gräser1, P M Vanhoutte.   

Abstract

The effect of severe hypoxia in quiescent or contracted (prostaglandin F2 alpha) canine coronary artery rings with and without endothelium was studied. Hypoxia induced an initial transient relaxation followed by a sustained contraction. The hypoxic contraction in quiescent rings was comparable in rings with and without endothelium. The facilitation of the contraction to prostaglandin F2 alpha was more pronounced in rings with endothelium. Increasing the level of contractions by augmenting the contraction of prostaglandin F2 alpha potentiated the hypoxic contraction in rings with endothelium only. Methylene blue, LY 83583, and nitro-L-arginine reversed the hypoxic facilitation in contracted rings into relaxation, whereas M&B 22948 augmented it. In quiescent coronary preparations, methylene blue reversed the hypoxic contraction into relaxation in preparations with and without endothelium, whereas nitro-L-arginine had the same effect in vessels with endothelium only. SIN-1, nitroglycerin, and dibutyryl guanosine 3',5'-cyclic monophosphate (cGMP) unmasked hypoxic facilitation in rings without endothelium. This was not observed with isoproterenol. The measurement of the level of cGMP revealed an increased level in rings with endothelium compared with those without endothelium under control oxygenation. This difference disappeared during hypoxia due to a decrease of cGMP content in vessels with endothelium. The results suggest that a moderate increase of the cGMP level in vascular smooth muscle is a prerequisite for the occurrence of hypoxia-induced facilitation in contracted canine coronary arteries.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661088     DOI: 10.1152/ajpheart.1991.261.6.H1769

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

1.  Chaotic behavior of the coronary circulation.

Authors:  Jerome Trzeciakowski; William M Chilian
Journal:  Med Biol Eng Comput       Date:  2008-05       Impact factor: 2.602

2.  PDE and sGC hand in hand to see the light.

Authors:  Paul M Vanhoutte
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-02       Impact factor: 11.205

3.  Tissues cIMPly do not lie.

Authors:  Yuansheng Gao; Paul M Vanhoutte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-07-23       Impact factor: 3.000

4.  Activation of NQO-1 mediates the augmented contractions of isolated arteries due to biased activity of soluble guanylyl cyclase in their smooth muscle.

Authors:  Charlotte M S Detremmerie; Susan W S Leung; Paul M Vanhoutte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-30       Impact factor: 3.000

Review 5.  Endothelium-dependent contractions in hypertension.

Authors:  Paul M Vanhoutte; Michel Feletou; Stefano Taddei
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

6.  KATP channel inhibition blunts electromechanical decline during hypoxia in left ventricular working rabbit hearts.

Authors:  Kara Garrott; Sarah Kuzmiak-Glancy; Anastasia Wengrowski; Hanyu Zhang; Jack Rogers; Matthew W Kay
Journal:  J Physiol       Date:  2017-03-13       Impact factor: 5.182

Review 7.  Endothelium-dependent contractions: when a good guy turns bad!

Authors:  Paul M Vanhoutte; Eva H C Tang
Journal:  J Physiol       Date:  2008-09-25       Impact factor: 5.182

8.  Cyclic GMP-phosphodiesterase inhibition does not alter cerebral oxygen consumption.

Authors:  H M Wei; A J Shah; J Tse; O Z Chi; H R Weiss
Journal:  Neurochem Res       Date:  1996-01       Impact factor: 3.996

9.  Non-endothelial endothelin counteracts hypoxic vasodilation in porcine large coronary arteries.

Authors:  Elise R Hedegaard; Edgaras Stankevicius; Ulf Simonsen; Ole Fröbert
Journal:  BMC Physiol       Date:  2011-05-15

Review 10.  Hypoxic Vasospasm Mediated by cIMP: When Soluble Guanylyl Cyclase Turns Bad.

Authors:  Yuansheng Gao; Zhengju Chen; Susan W S Leung; Paul M Vanhoutte
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.